MREO Mereo BioPharma Group plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · GBP | FY20212021-12-31 · GBP |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $500,000 | $0 | $10.00M | $0USD | 36.46M |
| Cost of revenue | — | — | — | -936,000 | 17.91M |
| Gross profit | — | — | — | — | 18.56M |
| R&D expense | $17.77M | $20.93M | $17.42M | 24.96M | 23.56M |
| SG&A expense | $23.01M | $26.43M | $18.42M | $26.11MUSD | — |
| Operating income | -$40.11M | -$47.36M | -$28.42M | -43.57M | -20.94M |
| Interest expense | $255,000 | $1.37M | $2.88M | 3.36M | 4.02M |
| Pretax income | -$41.88M | -$43.25M | -$30.00M | -36.09M | 14.24M |
| Income tax | $0 | $0 | -$532,000 | -1.90M | 1.52M |
| Net income | -$41.88M | -$43.25M | -$29.47M | -34.20M | 12.72M |
| EBITDA | -$39.95M | -$47.22M | -$28.25M | -42.84M | -20.29M |
| EPS (basic) | -0.05 | -0.06 | -0.04 | -0.06 | 0.02 |
| EPS (diluted) | -0.05 | -0.06 | -0.04 | -0.06 | -0.05 |
| Weighted avg. shares (diluted) | 797.12M | 739.62M | 659.45M | 603.20M | 555.28M |
| Balance sheet | |||||
| Cash & equivalents | $40.99M | $69.80M | $57.42M | 56.33M | 94.30M |
| Receivables | — | — | — | 762,000 | — |
| Current assets | $45.02M | $74.76M | $63.76M | 62.13M | 99.32M |
| PP&E, net | $137,000 | $257,000 | $405,000 | 1.83M | 2.53M |
| Intangibles | $516,000 | $643,000 | $1.09M | 24.12M | 24.56M |
| Total assets | $45.92M | $76.39M | $66.50M | 88.08M | 126.42M |
| Current liabilities | $4.30M | $13.85M | $9.49M | 24.68M | 12.54M |
| Short-term debt | — | — | — | 11.09M | 0 |
| Long-term debt | — | — | — | 0 | 14.38M |
| Total debt | — | — | — | 11.09M | 14.38M |
| Total liabilities | $5.00M | $15.42M | $15.96M | 26.21M | 38.41M |
| Shareholders' equity | $40.92M | $60.97M | $50.54M | $51.40MUSD | $92.20MUSD |
| Net debt | — | — | — | -45.25M | -79.91M |
| Cash flow statement | |||||
| Operating cash flow | -$30.97M | -$32.83M | -$21.13M | -38.82M | -5.24M |
| Capital expenditure | $20,000 | $0 | $0 | 10,000 | 535,000 |
| Free cash flow | -$30.99M | -$32.83M | -$21.13M | -38.83M | -5.77M |
| Investing cash flow | -$20,000 | -$699,000 | -$419,000 | 1.50M | -421,000 |
| Financing cash flow | $327,000 | $46.15M | $7.97M | -784,000 | 77.65M |
| Depreciation & amortization | $157,000 | $143,000 | $171,000 | 727,000 | 642,000 |
| Stock-based compensation | $7.60M | $7.39M | $4.92M | 3.86M | 3.30M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.